NCT07103668 2025-10-23A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer PatientsSuzhou Immunofoco Biotechnology Co., LtdPhase 3 Recruiting150 enrolled